Citadel Advisors
CLSD

Citadel Advisors’s Clearside Biomedical CLSD Stock Holding History

Citadel Advisors’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,774
Closed -$78.5K – 14607
2024
Q3 		$90.9K Sell
4,774
-1,668
-26% -$28.5K ﹤0.01% 11247
2024
Q2 		$126K Buy
6,442
+1,764
+38% +$34.1K ﹤0.01% 10591
2024
Q1 		$107K Buy
4,678
+1,622
+53% +$35K ﹤0.01% 11258
2023
Q4 		$53.6K Buy
3,056
+1,739
+132% +$24.8K ﹤0.01% 11714
2023
Q3 		$17.2K Buy
1,317
+160
+14% +$2.42K ﹤0.01% 12739
2023
Q2 		$19.4K Sell
1,157
-3,344
-74% -$57.6K ﹤0.01% 12745
2023
Q1 		$70.2K Buy
4,501
+4,329
+2,517% +$84.1K ﹤0.01% 11727
2022
Q4 		$2.89K Buy
+172
New +$3.1K ﹤0.01% 14272
2022
Q3 		– Sell
-1,018
Closed -$22.3K – 12717
2022
Q2 		$23K Sell
1,018
-1,058
-51% -$25.7K ﹤0.01% 12345
2022
Q1 		$71K Sell
2,076
-503
-20% -$15.1K ﹤0.01% 12561
2021
Q4 		$107K Sell
2,579
-13,333
-84% -$864K ﹤0.01% 12652
2021
Q3 		$1.43M Buy
15,912
+13,335
+517% +$1.18M ﹤0.01% 7200
2021
Q2 		$188K Buy
2,577
+915
+55% +$42.5K ﹤0.01% 12225
2021
Q1 		$62K Buy
+1,662
New +$83.4K ﹤0.01% 12791
2020
Q3 		– Sell
-8,872
Closed -$229K – 10131
2020
Q2 		$250K Buy
8,872
+4,482
+102% +$132K ﹤0.01% 8209
2020
Q1 		$112K Buy
4,390
+551
+14% +$20.4K ﹤0.01% 8552
2019
Q4 		$167K Buy
+3,839
New +$80.7K ﹤0.01% 8302
2019
Q3 		– Sell
-3,614
Closed -$53K – 9211
2019
Q2 		$53K Buy
3,614
+273
+8% +$4.87K ﹤0.01% 8714
2019
Q1 		$69K Sell
3,341
-927
-22% -$18.4K ﹤0.01% 8693
2018
Q4 		$68K Buy
4,268
+2,504
+142% +$117K ﹤0.01% 8403
2018
Q3 		$163K Sell
1,764
-3,128
-64% -$372K ﹤0.01% 8346
2018
Q2 		$784K Sell
4,892
-6,988
-59% -$1.18M ﹤0.01% 5625
2018
Q1 		$1.91M Buy
+11,880
New +$1.45M ﹤0.01% 3803
2017
Q3 		– Sell
-859
Closed -$117K – 7574
2017
Q2 		$117K Buy
+859
New +$103K ﹤0.01% 6850

Other funds holding CLSD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors's CLSD Position: Q4 2024 in Review

Citadel Advisors sold out of Clearside Biomedical (CLSD) in Q4 2024, closing a stake of 4,774 shares — an estimated $78.5K sold.

Citadel Advisors first reported a position in CLSD in Q2 2017 and held it in 24 quarters. The position peaked at $1.91M in Q1 2018. 43 funds tracked by Wall St. Rank hold CLSD as of Q4 2024.

  • Citadel Advisors reported no remaining Clearside Biomedical position as of Q4 2024 after selling out during the quarter.
  • Citadel Advisors sold 4,774 Clearside Biomedical shares in Q4 2024, an estimated $78.5K.
  • Citadel Advisors first reported a position in Clearside Biomedical in Q2 2017 and held it in 24 quarters.
  • Citadel Advisors's Clearside Biomedical position peaked at $1.91M in Q1 2018.
  • 43 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2024.

Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.